DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registry
Dan Turner(Shaare Zedek Medical Center), Frank M. Ruemmele(Délégation Paris 5), Jeffrey S. Hyams(Connecticut Children's Medical Center), J. C. Escher(Erasmus MC - Sophia Children’s Hospital), William A. Faubion(Mayo Clinic in Arizona), M Dubinsky, Robert N. Baldassano(Children's Hospital of Philadelphia), Jarosław Kierkuś(Children's Memorial Health Institute), Anne Robinson(AbbVie (United States)), Graham Heap(Queen Mary University of London), Sibylle Koletzko(LMU Klinikum), Joel R. Rosh(Cohen Children's Medical Center), Anne M. Griffiths(University of Toronto), Dilek Arikan(AbbVie (United States)), Harland S. Winter(Massachusetts General Hospital), J Petersson(AbbVie (United States)), V Kuehnl(AbbVie (Germany)), RK Russell(Royal Hospital for Children), Subra Kugathasan(Children's Healthcare of Atlanta)
Cited by 0
Related Papers
Human gut microbiome viewed across age and geography
|Nature|2012|7.9k
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k